Cethromycin: A promising new ketolide antibiotic for respiratory infections

Pharmacotherapy

Volumn 30, Issue 3, 2010, Pages 290-303

  Rafie, Sally ^a,b   MacDougall, Conan ^a   James, Charles L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

ABT 773; Antibiotic; CAP; Cethromycin; Community acquired pneumonia; Ketolide; Macrolide; Respiratory infections; Streptococcus pneumoniae

Indexed keywords

CETHROMYCIN; CLARITHROMYCIN; RANITIDINE; RIFAMPICIN; TELITHROMYCIN;

ACUTE SINUSITIS; ANTHRAX; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DYSGEUSIA; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HUMAN; LYMPHATIC SYSTEM DISEASE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SKIN DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; UROGENITAL TRACT DISEASE;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUGS, INVESTIGATIONAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KETOLIDES; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 77649230711     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.3.290     Document Type: Review

References (88)

1. Centers for Disease Control and Prevention. Fastats: pneumonia, September 2008. Available from www.cdc.gov/nchs/fastats/pneumonia.htm. Accessed January 24, 2009.
2. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37.
3. Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US study. J Clin Microbiol 2007;45:290-3.
4. Felmingham D, Canton R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001?004. J Infect 2007;55:111-18.
5. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-48.
6. Ortho-McNeil-Janssen. Tracking resistance in the United States today (TRUST) 12, 2007-2008; data on file. Titusville, NJ; June 3, 2009.
7. Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601-4.
8. Greene D. "Dear healthcare professional?letter. sanofi-aventis March 2007. Available from http://www.ketek.com/pdf/dhcpletter. pdf. Accessed July 19, 2007.
9. sanofi-aventis. Ketek (telithromycin) package insert. Bridgewater, NJ; 2007.
10. U.S. Food and Drug Administration. News: FDA announces label and indication changes for the antibiotic Ketek. February 2007. Available from http://www.fda.gov/bbs/topics/news/2007/new01561.html. Accessed July 19, 2007.
11. U.S. Food and Drug Administration. Patient safety news: narrower indications and new warnings for Ketek. April 2007. Available from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=62. Accessed July 19, 2007.
12. Gleason PP, Walters C, Heaton AH, Schafer JA. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Manag Care Pharm 2007;13:420-5.
13. Anonymous. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs R D 2007;8:95-102.
14. Lawrence LE. ABT-773 (Abbott Laboratories). Curr Opin Investig Drugs 2001;2:766-72.
15. Carbon CJ, Rubinstein E. Macrolides, ketolides, lincosamides and streptogramins. In: Cohen J, Powderly WG, eds. Infectious diseases, 2nd ed. Edinburgh, UK: Mosby, 2004:1791-803.
16. Bailey M, Chettiath T, Mankin AS. Induction of erm(C) expression by noninducing antibiotics. Antimicrob Agents Chemother 2008;52:866-74.
17. Tenson T, Mankin AS. Short peptides conferring resistance to macrolide antibiotics. Peptides 2001;22:1661-8.
18. Champney WS, Pelt J. The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells. Curr Microbiol 2004;45:155-60.
19. Nilius AM, Ma Z. Ketolides: the future of the macrolides? Curr Opin Pharmacol 2002;2:493-500.
20. Jenni S, Ban N. The chemistry of protein synthesis and voyage through the ribosomal subunit. Curr Opin Struct Biol 2003;13:212-19.
21. Vimberg V, Xiong L, Bailey M, Tenson T, Mankin A. Peptidemediated macrolide resistance reveals possible specific interactions in the nascent peptide exit tunnel. Mol Microbiol 2004;54:376-85.
22. Tipathi S, Kloss PS, Mankin AS. Ketolide resistance conferred by short peptides. J Biol Chem 1998;273:20073-7.
23. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Bio 2003;330:1005-14.
24. Capobianco JO, Cao Z, Shortridge VD, Ma Z, Flamm RK, Zhong P. Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000;44:1562-7.
25. Shakeri-Najed K, Stahlman R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006;7:639-51.
26. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39:577-85.
27. Boonefoy A, Girard AM, Agouridas C, Chantot JF. Ketolides lack inducibility properties of MLSB resistance phenotype. J Antimicrobial Chemother 1997;40:85-90.
28. Champney WS, Tober CL. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by eleven different ketolide antibiotics. Curr Microbiol 1998;37:418-25.
29. Jalava J, Katala J, Seppala H, Huovinen P. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species. Antimicrob Agents Chemother 2001;45:789-93.
30. Champney WS, Mentens N, Zurawick K. An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol 2004;49:239-47.
31. Shortridge VD, Zhong P, Cao Z, et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolidesusceptible and - resistant streptococci and staphylococci. Antimicrob Agents Chemother 2002;46:783-6.
32. Betriu C, Culebras E, Redondo M, et al. Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin. J Antimicrob Chemother 2002;50:436-8.
33. Morosini M-I, Canton R, Loza E, Campro RD, Almaraz E, Baquero F. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 2003;52:50-5.
34. Pendland SL, Neuhauser MM, Prause JL. In vitro bactericidal activity of ABT-773 and amoxicillin against erythromycinsusceptible and -resistant strains of Streptococcus pyogenes. J Antimicrobial Chemother 2002;49:671-4.
35. Schmitz FJ, Schwarz S, Milatovic D, Verhoef J, Fluit AC. In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella cattarhalis. J Antimicrob Chemother 2002;50:137-48.
36. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996;40:1817-24.
37. Tait-Kamradt A, Clancy J, Cronan M, et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41:2251-5.
38. Wierzbowski AK, Boyd D, Mulvey M, Hoban DJ, Zhanel GG. Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides. Antimicrob Agents Chemother 2005;49:4635-40.
39. Lunda VA, Xu ZQ, Eizhamer DA, Cannons AC, Cattani J. Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin. J Antimicrob Chemother 2008;62:639-40.
40. Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006;44:108-18.
41. Champney WS, Tober CL. Structure-activity relationships for six ketolide antibiotics. Curr Microbiol 2001;42:203-10.
42. Davies TA, Ednie LM, Hoellman DM, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother 2000;44:1894-9.
43. Brueggemann AB, Doern GV, Huynh HK, Wingert EM, Rhomberg PR. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 2000;44:447-9.
44. Johnson CN, Benjamin WH Jr, Gray BM, Crain MC, Edwards KM, Waites KB. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children. Int J Antimicrob Agents 2001;18:531-5.
45. Dubois J, St.-Pierre C. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens. Diagn Microbiol Infect Dis 2001;40:35-40.
46. Barry AL, Fuchs PC, Brown SD. In vitro activity of the ketolide ABT-773. Antimicrob Agents Chemother 2001;45:2922-4.
47. Stout JE, Sens K, Mietzner S, Obman A, Yu VL. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility. Int J Antimicrob Agents 2005;25:302-7.
48. Strigl S, Roblin PM, Reznik T, Hammerschlag MR. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1112-13.
49. Miyashita N, Fukano H, Yoshida K, Niki Y, Matsushima T. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2003;52:497-9.
50. Hammerschlag MR, Reznik T, Roblin PM, Ramirez J, Summersgill J, Bukofzer S. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother 2003;51:1025-8.
51. Waites KB, Crabb DM, Duffy LB. In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas. Antimicrob Agents Chemother 2003;47:39-42.
52. Jorgensen JH, Crawford SA, McElmeel ML, Whitney CG. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2004;48:605-7.
53. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007;44:S27-72.
54. Cao Z, Zhong P, Ruan Z, et al. Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae. Int J Antimicrob Agents 2004;24:362-8.
55. Nilius AM, Bui MH, Almer L, et al. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob Agents Chemother 2001;45:2163-8.
56. Hammerschlag MR, Roblin PM, Bebear CM. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother 2001;48:25-31.
57. Kim MK, Zhou W, Tessier PR, et al. Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 2002;46:3185-92.
58. Capitano B, Maglio D, Banevicius MA, Nightingale CH, Nicolau DP. Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model. Int J Antimicrob Agents 2003;22:588-93.
59. Azoulay-Dupuis E, Mohler J, Bedos JP, Barau C, Fantin B. Efficacy of cethromycin, a new ketolide, against Streptococcus pneumonia susceptible or resistant to erythromycin in a murine pneumonia model. Antimicrob Agents Chemother 2006;50:3033-8.
60. Rios AM, Mejias A, Chavez-Bueno S, et al. Impact of cethromycin (ABT-773) therapy on microbiological, histological, immunologic, and respiratory indices in a murine model of Mycoplasma pneumonia lower respiratory infection. Antimicrob Agents Chemother 2004;48:2897-904.
61. Edelstein PH, Higa F, Edelstein MAC. In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001;45:2685-90.
62. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin. Antimicrob Agents Chemother 2004;48:3508-15.
63. Pletz MW, Preechachatchaval V, Bulitta J, Allewelt M, Burkhardt O, Lode H. ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. Antimicrob Agents Chemother 2003;47:1129-31.
64. Katz DA, Grimm DR, Cassar SC, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004;75:516-28.
65. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005;49:2372-7.
66. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005;44:915-34.
67. Advanced Life Sciences. ABT-773 tablet: investigator's drug brochure, 9th ed. Woodridge, IL: Advanced Life Sciences, 2005.
68. Bukofzer S, Valdes J, Eiznhamer DA, et al. A phase II comparative study of the safety and efficacy of two oral doses of cethromycin for the treatment of community acquired pneumonia (CAP) [abstract L-1442]. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
69. Bukofzer S, Gu Y, Eiznhamer DA, et al. A phase 2/3 comparative study of the safety and efficacy of two oral doses of cethromycin for the treatment of community acquired pneumonia (CAP) [abstract L-1445]. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
70. Milanesio NA, English ML, Fredericks CE, et al. A comparative study of the safety and efficacy of cethromycin (CER) to clarithromycin (CLR) for the treatment of community acquired pneumonia (CAP) in adults (CL05?01) [abstract L-683]. Presented at the joint 48th interscience conference on antimicrobial agents and chemotherapy/45th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
71. Valdes J, Bukofzer S, Gu Y, et al. A phase 2 comparative study of the safety and efficacy of three oral doses of cethromycin for the treatment of acute bacterial sinusitis (ABS) [abstract 209]. Presented at the 44th annual meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12-15, 2006.
72. Bukofzer S, Gu Y, Eiznhamer DA, et al. A phase 2/3 comparative study of the safety and efficacy of cethromycin 150 mg QD vs cethromycin 150 mg BID for the treatment of acute bacterial sinusitis (ABS) [abstract 210]. Presented at the 44th annual meeting of the Infectious Diseases Society of America. Toronto, Ontario, Canada, October 12?5, 2006.
73. Valdes J, Bukofzer S, Eiznhamer DA, et al. A phase 2 comparative study of the safety and efficacy of three oral doses of cethromycin for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) [abstract L-1443]. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
74. Bukofzer S, Gu Y, Eiznhamer DA, et al. A phase 3 comparative study of cethromycin 150 mg QD and levofloxacin 500 mg QD for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) [abstract L-1444]. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
75. U.S. Food and Drug Administration. Cumulative list of orphan designated products. July 2007. Available from http://www.fda.gov/orphan/ designat/designytd.rtf. Accessed August 10, 2007.
76. Heine HS, Miller L, Bassett J, et al. Antimicrobial activity of cethromycin, a novel ketolide, tested against diverse collections of Bacillus anthracis (BA) and Yersinia pestis (YP) [abstract E-1853]. Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
77. Gustavson LE, Ye X, Beason J, et al. ABT-773 has no clinically important effect on the pharmacokinetics and safety of theophylline [abstract A-941]. Presented at the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001.
78. Ciervo CA, Shi J. Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections. Curr Med Res Opin 2005;21:1641-50.
79. Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. Pharmacotherapy 2005;25:42-51.
80. Shi J, Chapel S, Montay G, et al. Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther 2005;43:123-33.
81. Nenciu LM, Laberge P, Thirion DJ. Telithromycin-induced digoxin toxicity and electrocardiographic changes. Pharmacotherapy 2006;26:872-6.
82. Démolis J-L, Vacheron F, Cardus S, Funch-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther 2003;73:242-52.
83. Fredericks CE, Morganroth J, English ML, et al. A thorough QT study to define the ECG effects of cethromycin using a clinical and supratherapeutic dose compared to placebo and moxifloxacin in healthy subjects (CL07-001). Presented at the joint 48th interscience conference on antimicrobial agents and chemotherapy/46th annual meeting of the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
84. Bukofzer S, Gustavson L, Eiznhamer DA, et al. Assessment of the pharmacokinetic interaction between cethromycin and ketoconazole [abstract 444]. Presented at the 45th annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007.
85. Bukofzer S, O'Dea R, Gustavson L, et al. Assessment of the pharmacokinetic interaction between cethromycin and rifampin [abstract 443]. Presented at the 45th annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007.
86. Bukofzer S, Gustavson L, Xu Z-Q, et al. Single-dose bioavailability of cethromycin granules for suspension formulation in healthy adult subjects [abstract 450]. Presented at the 45th annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007.
87. Bukofzer S, Gustavson L, Eiznhamer DA, et al. Safety and pharmacokinetics of cethromycin following administration of single and multiple doses to subjects with severe renal impairment [abstract A-797]. Presented at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
88. Bukofzer S, Gustavson L Eiznhamer DA, et al. Safety and pharmacokinetics of cethromycin following administration of single and multiple doses to subjects with mild and moderate chronic hepatic insufficiency [abstract A-796]. Presented at the 47th interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.